BG-12 filing data put pressure on Aubagio and Gilenya sales strategies
This article was originally published in Scrip
Executive Summary
Detailed results from two pivotal clinical trials evaluating Biogen Idec's oral BG-12 (dimethyl fumarate) for the treatment of multiple sclerosis (MS) were published in the 20 September issue of the New England Journal of Medicine (NEJM).